Selective,highaffinity5-HT1Areceptorantagonist(Ki=0.6nMinvitro).Enhancestheactionofselective5-HTreuptakeinhibitorsandreversescitalopram-induced(Cat.No.1427)inhibitionofSEROtonergiccellfiring.
SoldforresearchpurposesunderagreementfromAstraZeneca
NAD299hydrochlorideisalsoofferedaspartoftheTocriscreenPlus.FindoutmoreaboutcompoundlibrariesavailablefromTocris.
Thetechnicaldataprovidedaboveisforguidanceonly.ForbatchspecificdatarefertotheCertificateofAnalysis.
AllTocrisproductsareintendedforlaboratoryresearchuseonly.
Thefollowingdataisbasedontheproductmolecularweight354.85.Batchspecificmolecularweightsmayvaryfrombatchtobatchduetosolventofhydration,whichwillaffectthesolventvolumesrequiredtopreparestocksolutions.